CoChat

Long-acting injectable versus daily oral antipsychotic treatment trials in schizophrenia: pragmatic versus explanatory study designs

Open access
Bossie, Cynthia A., Alphs, Larry D., Correll, Christoph U. · 2015 · International Clinical Psychopharmacology

The DOI matches its Crossref record, with a small difference in title or year; 29 of the 29 references it cites were found in a registry or an index.

Abstract

Trial design characteristics related to the explanatory : pragmatic spectrum may contribute toward the inconsistent results reported in studies comparing long-acting injectable (LAI) versus daily oral antipsychotic (AP) treatments in schizophrenia. A novel approach examined the hypothesis that a more pragmatic design is important to show the advantages of LAI versus oral APs. A literature search identified comparative studies assessing the clinical efficacy/effectiveness of LAI versus oral APs in more than 100 schizophrenia patients, with 6-month or more duration/follow-up, and published between January 1993 and December 2013 (n=11). Each study's design was rated using the six-domain ASPECT-R (A Study Pragmatic : Explanatory Characterization Tool-Rating). Nonparametric Wilcoxon rank-sum tests compared ratings of studies supporting (n=7) and not supporting (n=4) a LAI advantage. ASPECT-R total and domain scores were significantly higher (more pragmatic) in studies finding a LAI versus oral AP treatment advantage than those that did not. The rank order of this significance among domains was as follows: 'participant compliance assessment' (P=0.005), 'medical practice setting/practitioner expertise' (P=0.006), 'intervention flexibility' (P=0.007), 'follow-up intensity/duration' (P=0.009), 'primary trial outcomes' (P=0.012), and 'participant eligibility' (P=0.015). Findings support that more pragmatic, less explanatory design features are important to show advantages for LAI treatment. Explanatory studies may introduce features that obscure advantages related to adherence.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/yic.0000000000000082

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Flow chart of identification, screening and eligibility, and inclusion of clinical trials. AP, antipsychotic; LAI, long-acting injectable.
Fig. 1 Flow chart of identification, screening and eligibility, and inclusion of clinical trials. AP, antipsychotic; LAI, long-acting injectable.CC BY-NC-ND · PubMed Central
Fig. 2 ASPECT-R ratings for the seven studies that concluded an advantage of long-acting injectable versus oral daily antipsychotic treatment in patients with schizophrenia. ASPECT-R, A Study Pragmatic : Explanatory Characterization Tool-Rating.
Fig. 2 ASPECT-R ratings for the seven studies that concluded an advantage of long-acting injectable versus oral daily antipsychotic treatment in patients with schizophrenia. ASPECT-R, A Study Pragmatic : Explanatory Characterization Tool-Rating.CC BY-NC-ND · PubMed Central
Fig. 3 ASPECT-R ratings for the four studies that concluded no advantage for a long-acting injectable versus oral daily antipsychotic treatment in patients with schizophrenia. ASPECT-R, A Study Pragmatic : Explanatory Characterization Tool-Rating.
Fig. 3 ASPECT-R ratings for the four studies that concluded no advantage for a long-acting injectable versus oral daily antipsychotic treatment in patients with schizophrenia. ASPECT-R, A Study Pragmatic : Explanatory Characterization Tool-Rating.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Research works printed but not linked: 3

  1. Macfadden, 2010, Psychiatry (Edgmont), 7, 23
  2. Sampson, 2013, Cochrane Database Syst Rev, 20, CD006196
  3. Zhu, 2008, Psychiatr Serv, 59, 315, 10.1176/ps.2008.59.3.315 · doi:10.1176/ps.2008.59.3.315 · Paper page

Cited by

See all 39

Metadata

Authors
Bossie, C. A., Alphs, L. D., & Correll, C. U.
Affiliations
  • Janssen (United States) (US)
  • Janssen Scientific Affairs (United States) (US)
  • Hofstra University (US)
Corresponding author
Bossie, Cynthia A.
Venue
International Clinical Psychopharmacology
Published
2015-09
Volume
30
Issue
5
Pages
272-281
ISSN
0268-1315 (ISSN-L)
OpenAlex
W626348225
Cited by
33
References
29
Citations by year
2026: 1 · 2025: 4 · 2024: 2 · 2023: 2 · 2022: 3 · 2021: 3 · 2020: 5 · 2019: 3 · 2018: 1 · 2017: 5 · 2016: 3 · 2015: 1
FWCI
2.70
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • International Clinical Psychopharmacology (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
Janssen Scientific Affairs
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
  • Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
Keywords
long-acting injectable antipsychotics, oral antipsychotics, schizophrenia, trial design, participant compliance, medication adherence
MeSH terms
Administration, Oral, Delayed-Action Preparations, Humans, Injections, Intramuscular, Research Design, Schizophrenia, Antipsychotic Agents, Pragmatic Clinical Trials as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-acting injectable versus daily oral antipsychotic treatment trials in schizophrenia: pragmatic versus explanatory study designs. https://app.cochat.ai/papers/10.1097/yic.0000000000000082
The paper
Bossie, C. A., Alphs, L. D., & Correll, C. U. (2015). Long-acting injectable versus daily oral antipsychotic treatment trials in schizophrenia: pragmatic versus explanatory study designs. International Clinical Psychopharmacology. https://doi.org/10.1097/yic.0000000000000082

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.